Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Cingulate Inc CING
$4.83
▼ -4.55%
($-0.23)
🎈 Low Float
Open
$5.01
Prev Close
$5.06
Day Range
$4.80 – $5.12
52W Range
$3.16 – $11.89
Market Cap
$70.24M
Beta
-0.90
EPS (TTM)
$-3.68
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-07 |
| Shares Out. | 13,470,000 |
| Website | cingulate.com/ ↗ |
| Phone | 13026365400 |
| Employees | 14 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$5.9M |
| Free Cash Flow | -$20.9M |
| Total Assets | $33.1M |
| Total Liabilities | $9.6M |
| Equity | $23.5M |
About Cingulate Inc
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Cingulate Inc is a publicly traded company under the ticker symbol CING on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)